EVENTS · CGEM
PEERS
EARNINGS
Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.
Cullinan Therapeutics fell after it released updated Phase 1 data for its CLN-049 blood cancer therapy ahead of presenting at the ASH meeting
| Series | 1W | 1M |
|---|---|---|
| CGEM | −19.7% | −23.1% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 3 | 6 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q2 FY2026 | −0.83 | −0.81 | +1.94% | — |
| Q1 FY2026 | −0.85 | −0.75 | +11.27% | — |
| Q4 FY2025 | −0.83 | −0.77 | +6.73% | — |
| Q3 FY2025 | −0.98 | −0.77 | +21.14% | — |
| Series | 1W | 1M |
|---|---|---|
| CGEM | −19.7% | −23.1% |
| Peers | +1.6% | +5.3% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 3 | 6 |
